(Q83841172)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Rapamycin and chronic kidney disease: beyond the inhibition of inflammation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

chronic renal insufficiency

1 reference

Liu Y

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1925-1927

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16724087%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001543

28 January 2020

exact match

0 references

cites work

Molecular basis of renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

An expanding role for mTOR in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Rapamycin: an anti-cancer immunosuppressant?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021

Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001543

7 January 2021